Making a case "for" focal therapy of the prostate in intermediate risk prostate cancer: current perspective and ongoing trials

被引：10

作者：

Wang, Alex Z. ^{[1
]}

Lebastchi, Amir H. ^{[1
,9
]}

O'Connor, Luke P. ^{[1
]}

Ahdoot, Michael ^{[1
]}

Mehralivand, Sherif ^{[2
]}

Yerram, Nitin ^{[1
]}

Taneja, Samir S. ^{[3
]}

George, Arvin K. ^{[4
]}

Sanchez-Salas, Rafael ^{[5
,6
]}

Ward, John F. ^{[7
]}

Laguna, Pilar ^{[8
]}

de la Rosette, Jean ^{[8
]}

Pinto, Peter A. ^{[1
]}

机构：

[1] NCI, Urol Oncol Branch, NIH, Bethesda, MD 20892 USA

[2] NCI, Mol Imaging Branch, NIH, Bethesda, MD 20892 USA

[3] NYU, Sch Med, Dept Urol, Div Urol Oncol,NYU Langone Hlth, New York, NY 10003 USA

[4] Michigan Med, Dept Urol, Ann Arbor, MI USA

[5] Inst Mutualiste Montsouris, Dept Urol, Paris, France

[6] Univ Paris 05, Paris, France

[7] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA

[8] Istanbul Medipol Univ, Dept Urol, Istanbul, Turkey

[9] 10 Ctr Dr,Bldg 10,Room 1-5950, Bethesda, MD 20892 USA

来源：

WORLD JOURNAL OF UROLOGY | 2021年 / 39卷 / 03期

关键词：

Focal therapy; prostate cancer; MRI; WHOLE-GLAND CRYOTHERAPY; RADICAL PROSTATECTOMY; LASER-ABLATION; ACTIVE SURVEILLANCE; UNITED-STATES; INDEX LESION; FOLLOW-UP; OUTCOMES; MORTALITY; RADIATION;

D O I：

10.1007/s00345-020-03525-0

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Focal therapy is growing as an alternative management options for men with clinically localized prostate cancer. Parallel to the increasing popularity of active surveillance (AS) as a treatment for low-risk disease, there has been an increased interest towards providing focal therapy for patients with intermediate-risk disease. Focal therapy can act as a logical "middle ground" in patients who seek treatment while minimizing potential side effects of definitive whole-gland treatment. The aim of the current review is to define the rationale of focal therapy in patients with intermediate-risk prostate cancer and highlight the importance of patient selection in focal therapy candidacy.

引用

页码：729 / 739

页数：11

共 50 条

[41] Focal Therapy for Prostate Cancer: Complications and Their Treatment [J].

Rakauskas, Arnas ;

Marra, Giancarlo ;

Heidegger, Isabel ;

Kasivisvanathan, Veeru ;

Kretschmer, Alexander ;

Zattoni, Fabio ;

Preisser, Felix ;

Tilki, Derya ;

Tsaur, Igor ;

van den Bergh, Roderick ;

Kesch, Claudia ;

Ceci, Francesco ;

Fankhauser, Christian ;

Gandaglia, Giorgio ;

Valerio, Massimo .

FRONTIERS IN SURGERY, 2021, 8

[42] Focal Therapy for Prostate Cancer: Pending Questions [J].

Cathelineau, Xavier ;

Sanchez-Salas, Rafael .

CURRENT UROLOGY REPORTS, 2016, 17 (12)

[43] Focal therapy for prostate cancer: Fact or fiction? [J].

Lecornet, Emilie ;

Moore, Caroline ;

Ahmed, Hashim Uddin ;

Emberton, Mark .

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2010, 28 (05) :550-556

[44] Focal Therapy for Prostate Cancer: Possibilities and Limitations [J].

Eggener, Scott ;

Salomon, Georg ;

Scardino, Peter T. ;

De la Rosette, Jean ;

Polascik, Thomas J. ;

Brewster, Simon .

EUROPEAN UROLOGY, 2010, 58 (01) :57-64

[45] Focal therapy for prostate cancer: the technical challenges [J].

Haworth, Annette ;

Williams, Scott .

JOURNAL OF CONTEMPORARY BRACHYTHERAPY, 2017, 9 (04) :383-389

[46] Can we deliver randomized trials of focal therapy in prostate cancer? [J].

Ahmed, Hashim U. ;

Berge, Viktor ;

Bottomley, David ;

Cross, William ;

Heer, Rakesh ;

Kaplan, Richard ;

Leslie, Tom ;

Parker, Chris ;

Relton, Clare ;

Stephens, Richard ;

Sydes, Matthew R. ;

Turnbull, Lindsay ;

van der Meulen, Jan ;

Vickers, Andrew ;

Wilt, Timothy ;

Emberton, Mark .

NATURE REVIEWS CLINICAL ONCOLOGY, 2014, 11 (08) :482-491

[47] Focal Therapy for Prostate Cancer: Recent Advances and Future Directions [J].

Wang, Alex ;

O'Connor, Luke P. ;

Yerram, Nitin K. ;

Nandanan, Naveen ;

Ahdoot, Michael ;

Lebastchi, Amir H. ;

Gurram, Sandeep ;

Chalfin, Heather ;

Pinto, Peter A. .

CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2020, 18 (02) :116-125

[48] Focal Therapy for Prostate Cancer. Rationale, Indications and Selection [J].

Gomez-Veiga, F. ;

Portela-Pereira, P. ;

Cozar-Olmo, J. M. ;

Ahmed, H. ;

Moore, C. ;

Dickinson, L. ;

Algaba, F. ;

Izquierdo, L. ;

Alcaraz Asensio, A. ;

Martinez-Breijo, S. ;

Emberton, M. .

ACTAS UROLOGICAS ESPANOLAS, 2014, 38 (06) :405-412

[49] Focal prostate cancer therapy. Capabilities, limitations and prospects [J].

Baumunk, D. ;

Blana, A. ;

Ganzer, R. ;

Henkel, T. ;

Koellermann, J. ;

Roosen, A. ;

Machtens, S. ;

Salomon, G. ;

Sentker, L. ;

Witzsch, U. ;

Koehrmann, K. U. ;

Schostak, M. .

UROLOGE, 2013, 52 (04) :549-556

[50] Surgical therapy for intermediate risk prostate cancer [J].

Schade, George R. ;

Wood, David P., Jr. .

UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2011, 29 (06) :833-836

← 1 2 3 4 5 →